A randomised, controlled multi-centre trial of 26 weeks of subcutaneous Liraglutide (a GLP1 receptor agonist), with or without continuous positive airway pressure (CPAP), in patients with Type 2 Diabetes Mellitus (T2DM) and Obstructive Sleep Apnoea (OSA)

Trial Profile

A randomised, controlled multi-centre trial of 26 weeks of subcutaneous Liraglutide (a GLP1 receptor agonist), with or without continuous positive airway pressure (CPAP), in patients with Type 2 Diabetes Mellitus (T2DM) and Obstructive Sleep Apnoea (OSA)

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity; Sleep apnoea syndrome; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ROMANCE
  • Most Recent Events

    • 02 Oct 2017 Status changed from recruiting to completed.
    • 04 Dec 2015 Accrual to date is 2%, according to United Kingdom Clinical research Network record.
    • 02 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top